Skip to main content

Recent News & Research

ASCO Educational Book logo
Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It? Coping With Cancer

Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?

*May 2022* Patients with cancer face a trajectory marked by emotional and physical distress that can be associated with both diagnosis and treatment. Fear of cancer recurrence or progression has been considered one of the most common unmet needs reported by patients diagnosed with both localized and metastatic disease. Fear…
laurabbook@gmail.com
July 3, 2022
FDA Food and Drug Admin Logo
FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics Advocacy

FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics

*May 2022* EGFR Resisters co-founder Jill Feldman participated as a panelist in this FDA Oncology Workship:  3a "Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics; and 3b "Opportunities to Improve Dose Optimization: Assessing Safety and Tolerability." Current strategies for determining the recommended dose(s) of anticancer agents for evaluation…
laurabbook@gmail.com
July 3, 2022
EGFR Resister Logo
Drs. Christine Lovly and Helena Yu discuss and answer questions about their research projects funded by the EGFR Resisters ResearchTreatments

Drs. Christine Lovly and Helena Yu discuss and answer questions about their research projects funded by the EGFR Resisters

*May 2022* Dr. Upal Basu Roy from the LUNGevity Foundation conducts discussions with Drs. Christine Lovly and Helena Yu, along with EGFR Resisters co-founders Ivy Elkins and Jill Feldman. Both Lovely and Yu received research awards from the EGFR Resisters and provide updates on their projects in this video. Dr.…
laurabbook@gmail.com
July 3, 2022
Targeted Oncology
EGFR Tyrosine Kinase Inhibitors and SCLC Transformation ResearchTreatments

EGFR Tyrosine Kinase Inhibitors and SCLC Transformation

*April 2022* Ravi Salgia, MD, medical oncologist, professor, and chair, Department of Medical Oncology & Therapeutics Research, and Arthur & Rosalie Kaplan chair in Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, explains how treatment with a tyrosine kinase inhibitor (TKI) in patients with non–small cell…
laurabbook@gmail.com
July 3, 2022
Onc Live
Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer ResearchTreatments

Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

*April 2022* Note: Current guidelines state that molecular testing should be conducted at the time of initial diagnosis as well as tumor progression on targeted therapies. Meghan J. Mooradian, MD: I think an important question that many clinicians are faced with now is whether to use blood-based assays, tissue-based assays,…
laurabbook@gmail.com
June 29, 2022
Nature Communications
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer ResearchTreatments

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

*June 2021* Note: Most research in resistance has been studied in isolation, not accounting for the complexity tumor heterogeneity and the patient heterogeneity. This model was presented at one of the plenary sessions, considers the complex pharmacokinetics and variability of drug concentration in patients, specifically the change in concentrations of multiple…
laurabbook@gmail.com
June 29, 2022